Previous Close | 26.77 |
Open | 26.53 |
Bid | 26.80 x 800 |
Ask | 42.83 x 900 |
Day's Range | 25.59 - 27.04 |
52 Week Range | 21.06 - 79.75 |
Volume | |
Avg. Volume | 433,903 |
Market Cap | 1.255B |
Beta (5Y Monthly) | 1.37 |
PE Ratio (TTM) | 19.95 |
EPS (TTM) | 1.34 |
Earnings Date | May 05, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 66.88 |
Subscribe to Yahoo Finance Plus to view Fair Value for PRTA
With its stock down 30% over the past three months, it is easy to disregard Prothena (NASDAQ:PRTA). However, a closer...
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday June 8, 2022 at 8:30 AM ET. A live webcast of the fireside chat can be accessed through the investor relations section of